Proprietary information

23andMe Confidential and Proprietary Information

$2.6B average cost of drug development 3 ~90% failure rate 2, 3 7 years average time - to - IND 1

Drug Development is Inefficient

Limited Use of Data and Lack of Patient Engagement Constrains Productivity
1 IND = Investigational New Drug Application. fdareview.org, “The Drug Development and Approval Process” (2020).
2 Probability of success for a drug to be approved is estimated to be <12%.
3 PhRMA, “Biopharmaceutical Research & Development: The Process Behind New Medicines” (2015).

Genetic Data Helps Drive Behavior Change

• Eat healthier
• Set future goals to be healthier
• Adopt a healthier lifestyle in general
• Exercise more
• Get more rest / sleep
• Stop drinking / drink less
• Stop smoking / smoke less
  76% Report taking a positive health action 1
  1 Based on 2019 online survey, designed by 23andMe and M/A/R/C Research, of 1,046 23andMe Health + Ancestry customers.

We Pioneered Digital D2C Healthcare to Empower Customers With Affordable, Direct Access

1. 2015 Carrier Status (inherited conditions)
2. 2016 GHR (genetic health risk)
3. 2018 PGt (pharmacogenetic metabolism)
4. 2019 MUTYH (colorectal cancer)
5. 2017 BRCA (breast and ovarian cancer)
6. 2020 PGt (pharmacogenetic drug response)
   Proven accuracy (99% NPV/PPV) and accessibility
   TIME MAGAZINE INVENTION OF THE YEAR 6
   FDA Authorizations
   1 See FDA De Novo Authorizations 140044, 160026, 170046 and 180028 and FDA 510K Clearances K182784 and K193492.

Consumer Powered Healthcare Flywheel

Consumer Research

• Therapeutics / Product
• 80% Opt - In to Research 1
  1 Based on internal estimates subject to scientific, development and compliance risks.

We Are Redefining Healthcare. With Data. At Scale.

• 10.7M Genotyped Customers
• 4B+ Phenotypic Data Points
• Developing Therapeutics

Genetics - Based Primary Care

Genetics - Based Approach Will Transform the Continuum of Care

• 70% Providers think genetic tests will improve clinical outcomes 1
  1 Health Affairs, “Views Of Primary Care Providers On Testing Patients For Genetic Risks For Common Chronic Diseases.” (2018).

Subscription is the Next Phase of Our D2C Journey

1. Pharmacogenetics 3 reports (FDA - Authorized)
2. Heart Health Reports: Atrial Fibrillation, Coronary Artery Disease, LDL Cholesterol, Hypertension
3. DNA Relatives Advanced filters, access up to 5,000 relatives
4. Polygenic Risk Scores (Powered by 23andMe Research)

Providing Customers With Key, Actionable Insights

"Like me, there are many women who have slipped through the cracks of our current medical screening system..."
23andMe customer who discovered she had a BRCA1 mutation

Disclaimer

This presentation (this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation of the proposed transaction (the “Transaction”) between VG Acquisition Corp. (“VG”) and 23andMe, Inc. (“23andMe”).
This Presentation does not constitute investment, tax or legal advice.

Forward - Looking Statements
This Presentation may contain certain “forward - looking statements” including statements regarding VG’s and its management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future.

Intellectual Property
All rights to trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners.

Industry and Market Data
This Presentation relies on certain information and statistics based on 23andMe’s management’s estimates, and/or obtained from third party sources.